Holen Sie sich die Stockscreener-App
7.66
0.26%
0.02
Vorhandelsmarkt:
7.69
0.03
+0.39%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trading Action: Can BioCryst Pharmaceuticals Inc stock hit analyst price targetsJuly 2025 Catalysts & Trade Opportunity Analysis Reports - BỘ NỘI VỤ
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Jump Financial LLC - MarketBeat
JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Would You Still Hold BioCryst Pharmaceuticals Stock If It Fell 30%? - Trefis
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership - MarketBeat
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why BioCryst Pharmaceuticals Inc. stock is seen as undervalued2025 Short Interest & Verified Short-Term Trading Plans - Newser
Is BioCryst Pharmaceuticals Inc. stock a good choice for value investorsVolume Spike & Reliable Price Action Trade Plans - Newser
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $646,128.40 in Stock - MarketBeat
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock - MarketBeat
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
BioCryst Pharma (BCRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Panagora Asset Management Inc. Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How BioCryst Pharmaceuticals Inc. stock reacts to global recession fearsPortfolio Profit Report & Free Community Consensus Stock Picks - Newser
BioCryst receives antitrust clearance for Astria acquisition By Investing.com - Investing.com Canada
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
BioCryst Pharmaceuticals Officer Sells Over 161K Shares - TradingView
Officer Barnes Files To Sell 19,770 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update - Yahoo Finance
Biocryst receives early termination of Hart-Scott-Rodino waiting period for Astria acquisition - marketscreener.com
BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle - marketscreener.com
BioCryst Pharmaceuticals Inc Announces Early HSR Termination for Astria Merger - TradingView
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst receives antitrust clearance for Astria acquisition - Investing.com India
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
Prudential Financial Inc. Sells 159,975 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is BioCryst Pharmaceuticals Inc. stock resilient to inflation - Newser
Can BioCryst Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Action & Risk Managed Trade Strategies - Newser
Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - news.stocktradersdaily.com
FDA’s docket holds 16 more PDUFA dates by year-end - BioCentury
BioCryst Pharmaceuticals, Inc. $BCRX Shares Purchased by Legal & General Group Plc - MarketBeat
Officer Barnes Files To Sell 91,004 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView
Vinva Investment Management Ltd Takes $478,000 Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst to buy Astria Therapeutics for $13 per share (update) - MSN
Elo Mutual Pension Insurance Co Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Astria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, Hold - Seeking Alpha
BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers - Finviz
Jefferies Financial Group Inc. Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Geode Capital Management LLC Has $45.30 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Segall Bryant & Hamill LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Cash per share of BioCryst Pharmaceuticals, Inc. – FWB:BO1 - TradingView
Neo Ivy Capital Management Takes $810,000 Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Technical Reactions to BCRX Trends in Macro Strategies - news.stocktradersdaily.com
BioCryst to Present at Morgan Stanley Global Healthcare Conference - AOL.com
Biotech Stocks Facing FDA Decision In December 2025 - RTTNews
Why BioCryst (BCRX) Might be Well Poised for a Surge - sharewise.com
4.87%
4.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):